Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 20/20 | 0.79 |
| ▸ | BRD2 | P25440 | 2/20 | 0.79 |
| ▸ | SMCHD1 | A6NHR9 | 1/20 | 0.79 |
| ▸ | MYO1G | B0I1T2 | 1/20 | 0.79 |
| ▸ | AIP | O00170 | 1/20 | 0.79 |
| ▸ | AP3B1 | O00203 | 1/20 | 0.79 |
| ▸ | PSMD11 | O00231 | 1/20 | 0.79 |
| ▸ | CDC7 | O00311 | 1/20 | 0.79 |
| ▸ | SAP18 | O00422 | 1/20 | 0.79 |
| ▸ | KPNA3 | O00505 | 1/20 | 0.79 |
| ▸ | PPP6C | O00743 | 1/20 | 0.79 |
| ▸ | TCERG1 | O14776 | 1/20 | 0.79 |
| ▸ | UBE2L6 | O14933 | 1/20 | 0.79 |
| ▸ | PPP1R12A | O14974 | 1/20 | 0.79 |
| ▸ | U2SURP | O15042 | 1/20 | 0.79 |
| ▸ | SETD1A | O15047 | 1/20 | 0.79 |
| ▸ | ARPC1B | O15143 | 1/20 | 0.79 |
| ▸ | POLR1C | O15160 | 1/20 | 0.79 |
| ▸ | OGT | O15294 | 1/20 | 0.79 |
| ▸ | PPM1G | O15355 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16948393 | 1.00 | BRD4 (0.79) | BRD4BRD2SMCHD1MYO1GAIP | |
| SCHEMBL14757043 | 0.99 | BRD4 (0.80) | BRD4BRD2SMCHD1MYO1GAIP | |
| SCHEMBL14757289 | 0.97 | BRD4 (0.81) | BRD4BRD2SMCHD1MYO1GAIP | |
| Trifluoroacetic Acid SCHEMBL1819076 | 0.96 | BRD4 (0.72) | BRD4BRD2SMCHD1MYO1GAIP | |
| SCHEMBL25271529 | 0.94 | BRD4 (0.81) | BRD4BRD2SMCHD1MYO1GAIP | |
| SCHEMBL21139000 | 0.94 | BRD4 (0.69) | BRD4BRD2SMCHD1MYO1GAIP | |
| SCHEMBL14756138 | 0.94 | BRD4 (0.83) | BRD4BRD2SMCHD1MYO1GAIP | |
| SCHEMBL15981816 | 0.93 | BRD4 (0.80) | BRD4BRD2SMCHD1MYO1GAIP | |
| SCHEMBL11984944 | 0.92 | BRD4 (0.67) | BRD4BRD2SMCHD1MYO1GAIP | |
| SCHEMBL15981815 | 0.92 | BRD4 (0.81) | BRD4BRD2SMCHD1MYO1GAIP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
| US-20230040299-A1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2023-02-09 | — | — | US | disclosed |
| US-20230040299-A1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2023-02-09 | — | — | US | disclosed |
| EP-3589618-B1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-11478478-B2 | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-10-25 | — | — | US | disclosed |
| EP-3692026-B1 | BENZOFURAN DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS. | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| US-11319307-B2 | 2,3-dihydrobenzohurans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| US-11319307-B2 | 2,3-dihydrobenzohurans as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| US-11273146-B2 | Benzofuran derivatives and their use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2022-03-15 | — | — | US | disclosed |
| WO-2011054843-A1 | BROMODOMAIN INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054843-A1 | BROMODOMAIN INHIBITORS FOR TREATING AUTOIMMUNE AND INFLAMMATORY DISEASES | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054553-A1 | BENZODIAZEPINE BROMODOMAIN INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054848-A1 | THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054846-A1 | IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054846-A1 | IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054553-A1 | BENZODIAZEPINE BROMODOMAIN INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054848-A1 | THETRAHYDROQUINOLINES DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054845-A1 | BENZODIAZEPINE BROMODOMAIN INHIBITOR | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011054841-A1 | TETRAHYDROQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXOSMITHKLINE LLC (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11273146-B2 | Benzofuran derivatives and their use as bromodomain inhibitors | BRD4, BRD3, BRPF3 | BRD4 1/4885BRD2 5/4885SMCHD1 1347/4885 |
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | BRD4 331/4885BRD2 497/4885SMCHD1 1926/4885 |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | BET1, BRD4, PHKB | BRD4 2/4885BRD2 12/4885SMCHD1 1053/4885 |
| US-20230040299-A1 | 2,3-DISUBSTITUTED 1-ACYL-4-AMINO-1,2,3,4-TETRAHYDROQUINOLINE DERIVATIVES AND THEIR USE AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | BRD4 1/4885BRD2 3/4885SMCHD1 3710/4885 |
| US-11478478-B2 | 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors | BRD4, BRD3, BRD2 | BRD4 1/4885BRD2 3/4885SMCHD1 3710/4885 |
| US-11319307-B2 | 2,3-dihydrobenzohurans as bromodomain inhibitors | BRD4, BRD3, BRPF3 | BRD4 1/4885BRD2 4/4885SMCHD1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.